The following is a summary of the Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Bio-Path Holdings reported a net loss of $3.2 million or $4.88 per share for Q1 2024, which is an improvement from a net loss of $5.3 million or $13.25 per share for Q1 2023.

• The company's cash balance as of March 31, 2024, was $0.2 million.

• Research and development expenses decreased to $2.3 million, while general and administrative expenses mildly increased to $1.4 million.

• After Q1, the company secured additional funding of $3.5 million through an at-the-market offering agreement and registered direct offering.

Business Progress:

• Bio-Path made significant advancements by receiving newly issued patents in Mexico, Australia, and Japan.

• It achieved clinical trial progress with positive interim results for acute myeloid leukemia treatment with its lead product candidate, Prexigebersen.

• The company plans to pursue FDA expedited programs for Fast Track designation for Prexigebersen AML treatment.

• Progress was noted in the BP1002 program, targeting the Bcl-2 protein and showing encouraging results in dose escalation studies.

• The Phase 1/1b clinical trial for BP1001-A for solid tumor types was launched, and progress was also made with the BP1003 program targeting the STAT3 protein.

• Processes are underway to submit an investigational new drug (IND) application to the FDA for BP1003.

More details: Bio-Path Holdings IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.